SLRXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:35):

Stats
本日の出来高	9 794.00
平均出来高	109 993
時価総額	2.22M
EPS	$0 ( 2024-03-25 )
次の収益日	( $-6.70 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0130 (2.79%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Arthur David J.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Rosenblum Mark J	Buy	22 500	Stock Option (right to buy)
2024-02-20	Mcvicar William K.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Mccreedy Bruce J Jr.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Lieber Jonathan I	Buy	20 500	Stock Option (right to buy)

INSIDER POWER
100.00
Last 99 transactions
Buy: 2 809 420 \| Sell: 0

Salarius Pharmaceuticals 相関

10 最も正の相関
OTLY	0.838
TCON	0.807

10 最も負の相関
BNIXU	-0.818

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Salarius Pharmaceuticals 財務諸表

Annual	2023
収益:	$0
総利益:	$-10 051.00 (0.00 %)
EPS:	$-3.84

FY	2023
収益:	$0
総利益:	$-10 051.00 (0.00 %)
EPS:	$-3.84

FY	2022
収益:	$0
総利益:	$-6 677.00 (0.00 %)
EPS:	$-14.77

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-7.72

Financial Reports:

No articles found.

Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.